蔗糖铁注射液联合促红细胞生成素治疗癌症相关贫血的临床观察

doi:10.3971/j.issn.1000-8578.2011.03.019

蔗糖铁注射液联合促红细胞生成素治疗癌症相关贫血的临床观察

Clinical Observation of Iron Sucrose Combined with rHuEPO in Treatment of Cancer-related Anemia

摘要

摘要: 目的观察蔗糖铁注射液联合促红细胞生成素（rHuEPO）治疗癌症相关贫血的疗效、安全性和对患者生活质量的影响。方法将56例癌症相关贫血患者随机分为两组各28例：治疗组静脉滴注蔗糖铁每次100mg，2次/周；对照组口服富马酸亚铁每次300mg，3次/日；两组均同时皮下注射rHuEPO 40 000 IU/周；疗程为6周。观察治疗前后贫血状况和铁代谢指标的变化及治疗的安全性，并应用卡氏功能状态（KPS）进行生活质量测评。结果治疗组与对照组比较血红蛋白（Hb）、红细胞压积（Hct）、铁蛋白（SF）和转铁蛋白饱和度（TSAT）均明显升高（P<0.001），患者的主观症状和生活质量有明显改善（P<0.05），且不良反应发生率低（P<0.05）。结论蔗糖铁注射液联合rHuEPO治疗癌症相关性贫血的疗效和安全性，优于富马酸亚铁联合rHuEPO，并能够提高患者生活质量。

Abstract: ObjectiveTo investigate the curative effect, safety and impact of Iron Sucrose combined with rHuEPO on quality of life of cancer-related anemia. MethodsFifty-six cases of cancer-related anemia were randomly divided into two groups. The patients in EG were treated by Iron Sucrose, iv 100mg/d, 2d/w. The patients in CG were treated by Ferrous fumarate, p.o. 300mg tid. All patients were treated by rHuEPO ih 40 000 IU/w. The quality of life was measured by KPS. ResultsThe Hb, Hct, SF, TSAT（P<0.001）,the symptoms related to anemia and quality of life（P<0.05） of patients in EG were obviously improved, and had a lower IN of adverse effect（P<0.05）. ConclusionThe curative effect, safety and impact on quality of life of Iron Sucrose combined with rHuEPO on patients of cancer-related anemia were better than those of Ferrous fumarate combined with rHuEPO.

HTML全文

参考文献(0)

施引文献

资源附件(0)